Caprock Group LLC Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

Caprock Group LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,886 shares of the company’s stock, valued at approximately $203,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Intrinsic Value Partners LLC lifted its holdings in Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after purchasing an additional 24,505 shares during the last quarter. Banco Santander S.A. bought a new stake in shares of Moderna in the third quarter valued at approximately $3,550,000. John G Ullman & Associates Inc. lifted its stake in shares of Moderna by 341.3% during the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after buying an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares during the period. Finally, Vontobel Holding Ltd. grew its stake in Moderna by 148.2% in the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after buying an additional 69,313 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of Moderna stock opened at $32.60 on Friday. The business’s 50-day moving average price is $40.22 and its 200-day moving average price is $58.87. The firm has a market capitalization of $12.55 billion, a PE ratio of -5.60 and a beta of 1.59. Moderna, Inc. has a 12 month low of $31.94 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the business earned ($1.39) earnings per share. Sell-side analysts forecast that Moderna, Inc. will post -9.18 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 2,664 shares of company stock valued at $115,210. Insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several recent research reports. Wolfe Research initiated coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Bank of America reissued an “underperform” rating and set a $41.00 price objective on shares of Moderna in a report on Tuesday, December 10th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Monday, November 18th. Berenberg Bank raised their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Finally, UBS Group reduced their price objective on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $67.26.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.